دانلود رایگان مقاله adropin و Salusins پپتیدهای جدید به طور بالقوه شامل متابولیسم لیپید و آترواسکلروز

Abstract

Dyslipidemia is one of the most potent risk factors for the development of atherosclerosis. The high atherosclerotic risk in dyslipidemic patients is associated with endothelial dysfunction. During the last two decades, novel bioactive peptides have emerged as potential biomarkers of endothelial dysfunction and dyslipidemia-salusins and adropin. Salusin-alpha is likely to prevent atherosclerosis, while salusin-beta may act as a potential proatherogenic factor. Adropin was recently identified as important for energy homeostasis and lipid metabolism. Adropin is closely related to the inhibition of atherosclerosis by up-regulation of the endothelial nitric oxide synthase expression through the vascular endothelial growth factor receptor-2. These peptides represent a novel target to limit diseases characterized by endothelial dysfunction and may form the basis for the development of new therapeutic agents for treating metabolic disorders associated with atherosclerosis.

3. Conclusions

In summary, the pathogenesis of atherosclerosis is multifacto- rial, but at every step of this process, dyslipidemia or the imbalance between proatherogenic and antiatherogenic factors accelerate atherosclerosis. Salusin-alpha and salusin-beta show contrasting effects on atherosclerosis. They possess antiatherogenic and proatherogenic properties, respectively. Adropin seems to have a protective effect in relation to endothelial cells. Therefore, salusin- and adropin-based treatments could emerge as a new line of therapy against atherosclerosis and related diseases